Filing Flows › Standard Biotools (LAB) › Q4 2025
Standard Biotools (LAB) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
Standard Biotools (LAB) reported revenue of $23.8M for the fourth quarter 2025 (Q4 2025), -4% from a year earlier and +22% from the quarter before. Operating margin was -103.6%, net earnings $19.3M (81.0% of revenue).
Standard Biotools, Q4 2025: revenue $23.8M (-4% year over year), operating margin -103.6%, net earnings $19.3M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.8M | +22% | -4% |
| Operating profit | −$24.6M | — | — |
| Net earnings | $19.3M | — | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $23.8M in Q4 2025, down 4% year over year and up 22% from the previous quarter. Consumables was the largest line at 38% of revenue.
Gross margin was 47.8%, up 2.0 points from a year earlier. Operating costs exceeded revenue by $24.6M, an operating margin of -103.6%. Operating expenses fell 4% while revenue fell 4%. The fastest-growing cost line was Research & development (+13%). Net earnings were $19.3M. Non-operating items added $8.0M, -48% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.2M. Non-cash charges added back $1.3M of depreciation and amortization and $5.7M of share-based compensation. Working capital and other items used $27.5M. Capital expenditures of $476K exceeded it, leaving free cash flow of −$1.7M.
Questions
What was Standard Biotools' revenue in the fourth quarter 2025?
Standard Biotools (LAB) reported revenue of $23.8M for the fourth quarter 2025 (Q4 2025), -4% from a year earlier and +22% from the quarter before.
Was Standard Biotools profitable in the fourth quarter 2025?
Operating loss was $24.6M (-103.6% of revenue) and net earnings $19.3M.
Source: Standard Biotools 10-K on SEC EDGAR.